Literature DB >> 35835638

Severe encephalopathy associated with SARS-CoV-2 Omicron BA.1 variant infection in a neonate.

Kenichi Tetsuhara1, Satoshi Akamine2, Yoshie Matsubara2, Shunsuke Fujii3, Wataru Kashimada4, Kentaro Marutani3, Michiko Torio5, Yuya Morooka6, Nozomu Hanaoka7, Tsuguto Fujimoto7, Haruna Nakamura-Miwa8, Satoru Arai8, Keiko Tanaka-Taya8, Kenji Furuno6, Yumi Mizuno9, Ryutaro Kira2.   

Abstract

INTRODUCTION: The coronavirus disease 2019 (COVID-19), including the Omicron variant, is less severe in children than in adults. To date, there has been no detailed description of COVID-19-associated severe encephalopathy due to the Omicron variant during the neonatal and early infantile periods. CASE
PRESENTATION: During the outbreak of the Omicron variant, a 29-day-old male presented with a pale and ill appearance. The patient was intubated for mechanical ventilation owing to recurrent apnea, which subsequently turned out to be a breath-holding that may have been caused by seizure. In addition, nonconvulsive status epilepticus was observed. Total duration of repetitive seizure activities was approximately 30 min per hour when seizures were most severe. Brain magnetic resonance imaging (MRI) on day 14 revealed extensive hyperintensity in the T2 sequence, hypointensity in the fluid-attenuated inversion recovery (FLAIR) sequence in the deep and subcortical white matter, and diffusion restriction in the corpus callosum. The Omicron BA.1 variant of the severe acute respiratory syndrome coronavirus 2 was detected in his respiratory sample. Follow-up MRI on day 45 revealed multiple cystic cavitations.
CONCLUSION: Although COVID-19 is not severe in most children, life-threatening conditions such as COVID-19-associated severe encephalopathy can occur during the neonatal and early infantile periods.
Copyright © 2022 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Coronavirus disease 2019 (COVID-19); Encephalomalacia; Neonate; Omicron variant; Severe encephalopathy

Year:  2022        PMID: 35835638      PMCID: PMC9273474          DOI: 10.1016/j.braindev.2022.06.010

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   2.272


Introduction

The coronavirus disease 2019 (COVID-19) is less severe in children than in adults [1], although it is slightly more severe in children under 1 year of age [2]. Neurological involvement occurs in 22–40% of children who require admission [3], [4]. It is occasionally associated with life-threatening conditions, such as severe encephalopathy [3], [5]. Little is known about COVID-19-associated encephalopathy during the neonatal and early infantile periods [6]. Herein, we report a case of a 28-day-old baby with COVID-19-associated severe encephalopathy caused by the Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Case presentation

A 28-day-old male experienced sneezing in January 2022 during the outbreak of the Omicron variant (day 1). The following day, he presented to the emergency department looking pale and ill. He was born at a gestational age of 37 weeks, with a birth weight of 3013 g and had an uneventful perinatal course. His newborn screening test, including lysosomal storage diseases, was negative. His mother's older brother who had epilepsy died at the age of 30 years due to unknown causes. The patient’s parents were unvaccinated against SARS-CoV-2. His father had developed COVID-19 one day before admission. On day 2, the patient appeared pale and ill. He developed apnea with bradycardia during ambulance transport. On arrival, his body weight was 3.7 kg, and his vital signs were as follows: respiratory rate of 58 bpm with oxygen saturation (SpO2) of 100% on room air, heart rate of 188 bpm, blood pressure of 98/72 mmHg, Glasgow Coma Scale score of E2V3M5, and axillary temperature of 36.3 °C. Physical examination revealed normal lung and heart sounds without increased respiratory effort and normal peripheral circulation. He developed apnea, and his SpO2 dropped below 50%, which improved with skin stimulation. Point-of-care ultrasonography did not reveal congenital heart disease. Chest radiography did not reveal any lung consolidation or cardiac enlargement. Venous blood gas analysis revealed the following: pH, 7.30; carbon dioxide, 60.2 mmHg; bicarbonate, 29.9 mmol/L; and lactate, 1.4 mmol/L. Head computed tomography did not reveal any abnormalities, such as ischemic changes, brain edema, or hemorrhage. The laboratory findings were as follows: white blood cell count, 7790/mm3; neutrophil count, 69.2%; lymphocyte count, 17.8%; hemoglobin, 10.4 g/dL; platelet count, 474,000/mm3; lactate dehydrogenase, 231 U/L; C-reactive protein, <0.03 mg/dL; ferritin, 226 ng/mL; D-dimer, <0.5 μg/mL; and fibrinogen, 191 mg/dL (Table 1 ). SARS-CoV-2 was detected using a multiplex polymerase chain reaction (PCR) system (FilmArray™ Respiratory Panel 2.1 [BioFire Diagnostics, Utah, USA]). No other pathogens, including pertussis and respiratory syncytial virus, were detected. He was intubated due to recurrent apnea and was admitted to the intensive care unit. We administered continuous midazolam for sedation. Cefotaxime and vancomycin were administered until the blood and urine cultures came out negative.
Table 1

Laboratory findings.

Day 2Day 5Day 11Day 29
White blood cell, /mm37,7902,5304,70012,380
Lactate dehydrogenase, U/L231178653196
C-reactive protein, mg/dL<0.030.070.41<0.03
Ferritin, ng/mL226.8276.81481.0220.4
Procalcitonin, ng/mL0.07
D-dimer, μg/mL<0.51.63.3
Fibrinogen, mg/dL191150163
Serum IL-6, pg/mL46.7<1.5
CSF IL-6, pg/mL11.8

IL-6; interleukin 6, CSF; cerebrospinal fluid.

Laboratory findings. IL-6; interleukin 6, CSF; cerebrospinal fluid. On day 3, the SpO2 recurrently dropped down to 30% without bradycardia under mechanical ventilation. During hypoxemia, although the airway resistance did not increase, the static compliance decreased based on the ventilator measurements. Therefore, the apnea was considered to be caused by breath-holding and not by the absence of respiratory effort. On day 4, continuous electroencephalography (cEEG) was started to differentiate seizure as the cause of breath holding. When breath-holding occurred, we immediately confirmed several times that no ictal pattern was observed on cEEG, and discontinued cEEG following a procedure on day 5. We administered a continuous neuromuscular blocking agent to suppress breath-holding, which was discontinued on day 5. Since we had to minimize the time spent in the patient's room where the cEEG was kept, we could not assess the EEG findings sufficiently. In the retrospective analysis, rhythmic spike or spike and wave complex of 1.5–2 Hz occurred mostly in the left hemisphere for several minutes at frequent intervals from day 4 (Fig. 1 A–C). Total duration of repetitive seizure activities is approximately 30 min per hour when seizures were most severe (Fig. 1D). We could not confirm ictal pattern during breath-holding because the video did not show the SpO2 monitor. From day 6, myoclonic movements occurred in the lower extremities several times per day. On day 7, after an episode of myoclonic movements in both lower limbs for a few seconds with conjugate eye deviation to the left, his SpO2 transiently decreased to 50%. We resumed cEEG after suspecting seizure. We confirmed the ictal pattern on cEEG when myoclonic movements occurred (Fig. 1E), and subsequently increased the dosage of midazolam and administered phenobarbital. Consequently, breath-holding, hypoxemia, myoclonic movements, and seizures on EEG disappeared. We discontinued cEEG on day 9.
Fig. 1

Electroencephalogram during nonconvulsive status epilepticus (NCSE) on day 4 revealing ictal onset (A), rhythmic spike or spike and wave complex of 1.5–2 Hz occurring in the left hemisphere (B), and ictal termination (C). Density spectral array during NCSE on day 4 (D). Ictal pattern during myoclonic movement on day 7 (E).

Electroencephalogram during nonconvulsive status epilepticus (NCSE) on day 4 revealing ictal onset (A), rhythmic spike or spike and wave complex of 1.5–2 Hz occurring in the left hemisphere (B), and ictal termination (C). Density spectral array during NCSE on day 4 (D). Ictal pattern during myoclonic movement on day 7 (E). Cerebrospinal fluid examination on day 11 revealed a white blood cell count of 2 /µL, protein of 57 mg/dL, and glucose of 72 mg/dL. The cultures were negative. Brain magnetic resonance imaging (MRI) on day 14 revealed hyperintensity on T2 and hypointensity on fluid-attenuated inversion recovery (FLAIR) sequence in the deep and subcortical white matter of the left frontal, bilateral temporal, and parietal lobes (Fig. 2 A–C). In addition, it showed hyperintensity on the diffusion-weighted sequence and a decreased apparent diffusion coefficient value in the corpus callosum (Fig. 2D-E). Finally, the patient was diagnosed with probable encephalitis due to the SARS-CoV-2 Omicron variant, following the diagnostic criteria for encephalitis by the International Encephalitis Consortium [7]. The metabolomic analysis using urine sample on day 8 (Japan Clinical Metabolomics Institute, Ishikawa, Japan) and the primary immunodeficiency panel (Kazusa DNA Research Institute, Chiba, Japan) were negative. We used comprehensive PCR methods (Fasttrack DIAGNOSTICS [Riken genesis, Tokyo, Japan]; FTD respiratory pathogens 21, FTD fever and rash, FTD viral meningitis, and FTD viral gastroenteritis) that are highly sensitive for detecting 32 different viruses associated with acute encephalitis and encephalopathy, testing spinal fluid, whole blood, serum, plasma, pharyngeal swab, fecal, and urine samples. These clinical specimens were properly stored. Only the SARS-CoV-2 gene was detected in the nasopharyngeal and stool specimens, but not in the other specimens. The whole-genome sequence of SARS-CoV-2 revealed the Omicron BA.1 variant (Fukuoka City Institute of Health and Environment, Fukuoka, Japan). He was extubated on day 9, discharged from the intensive care unit on day 13, and discharged home on day 30 without special health care needs. Brain MRI on day 45 revealed multiple cystic cavitations in the left cerebral hemisphere, right temporal, occipital, and parietal lobes, as well as left epidural fluid accumulation (Fig. 2F-G). The basal ganglia and thalamus were intact.
Fig. 2

Brain MRI on day 14 revealing hypo-intensity on T1 (A) and fluid-attenuated inversion recovery (C) sequence and hyper-intensity on T2 (B) in the deep and subcortical white matter of the left frontal, bilateral temporal to parietal lobes, and hyper-intensity on diffusion-weighted sequence (D) and decreased apparent diffusion coefficient value (E) in the corpus callosum (arrow). Fluid-attenuated inversion recovery sequence on day 45 revealing cystic cavitations in left cerebral hemisphere and right temporal, occipital, and parietal lobes and left epidural fluid accumulation (E, F).

Brain MRI on day 14 revealing hypo-intensity on T1 (A) and fluid-attenuated inversion recovery (C) sequence and hyper-intensity on T2 (B) in the deep and subcortical white matter of the left frontal, bilateral temporal to parietal lobes, and hyper-intensity on diffusion-weighted sequence (D) and decreased apparent diffusion coefficient value (E) in the corpus callosum (arrow). Fluid-attenuated inversion recovery sequence on day 45 revealing cystic cavitations in left cerebral hemisphere and right temporal, occipital, and parietal lobes and left epidural fluid accumulation (E, F).

Discussion

We describe a male with COVID-19-associated severe encephalopathy during neonatal and early infantile periods, who subsequently developed multiple cystic cavitations due to the Omicron BA.1 variant. Although there are case reports of COVID-19 encephalopathy with neuroimaging abnormalities in neonates [8], there have been no reports of COVID-19-associated encephalopathy during the neonatal and early infantile periods as severe as in this case. COVID-19 is less severe in children, especially within the Omicron predominance [1], [9], [10]. However, this could induce severe conditions. Neurological involvement associated with COVID-19 varies, and abnormal findings on brain imaging include severe encephalitis with or without cytotoxic lesions of the callosal splenium, acute necrotizing encephalopathy, acute disseminated encephalomyelitis, posterior reversible encephalopathy syndrome, vasculitis, and infarction [3], [11]. In the first MRI of this case, the hypointensity in the FLAIR sequence implies the encephalopathy in subacute phase. The corpus callosum can show residual cytotoxic edema due to infection [12]. Therefore, we consider that cytotoxic edema of the extensive white matter develops in the acute phase. This may represent the most severe form of COVID-19-associated encephalopathy. The suggested pathophysiology of COVID-19-induced central nervous system (CNS) dysfunction is as follows: (1) invasion of SARS-CoV-2 from the olfactory tract or angiotensin-converting enzyme 2 receptor to the CNS induces the release of pro-inflammatory cytokines from microglia and astrocytes; (2) COVID-19 breaks the blood–brain barrier, causing the entry of peripheral cytokines into the CNS; and (3) COVID-19 induces oxidative stress and mitochondrial dysfunction [13]. Corpus callosum lesions tend to develop in cytokinopathy because of the higher density of cytokines and glutamate receptors [12]. There are reports of corpus callosum lesions associated with SARS-CoV-2 infection in children, including multi-system inflammatory syndrome [14]. In this case, systemic inflammation, indicated by elevated ferritin or serum IL-6 level, was not severe and cerebrospinal fluid IL-6 in subacute phase was not high. Therefore, the encephalopathy may be due to the direct invasion of SARS-CoV-2, and vascular endothelial damage and/or localized cytokinopathy caused by COVID-19. Furthermore, we also noted cystic cavitations, which are caused by hypoxic-ischemic insults, toxic insults, infections, or metabolic disorders [15]. Encephalopathy with corpus callosum lesions associated with COVID-19, subsequently developing cystic cavitations, has also been reported [8]. In this case, ischemia could be caused by vascular endothelial damage. Hypoxia was unlikely because the findings did not reveal hypoxemia or shock sufficient to cause tissue hypoxia, the basal ganglia were intact, and cerebral abnormalities were asymmetrical on brain MRI. So far, we considered that encephalopathy was caused by COVID-19 in this case. However, congenital factors were not completely ruled out. Therefore, the possibility remains that COVID-19 could be a trigger for aggravating any underlying disease that was not known at that time. Due to severe encephalopathy, the present patient developed nonconvulsive status epilepticus (NCSE) [16]. Although there are reports of adults with COVID-19-associated NCSE with a prevalence of approximately 5% [17], it remains unclear in children. However, there are reports of NCSE in children due to non-COVID-19 causes [18]. In critically ill children with encephalopathy, nonconvulsive seizures has a frequency of 7 to 47% [19], with neonates tending to develop NCSE. Because NCSE is associated with unfavorable outcomes and can only be detected by EEG, we should use EEG in children with COVID-19 at risk of NCSE, such as those with altered mental status and young age [19]. We considered that the patient had developed central apnea on admission, subsequently turned out to be a breath-holding by ventilator measurements. Infections can cause apnea in neonates. For example, respiratory syncytial virus infection has been proposed to cause apnea by disrupting the neural control pathway [20]. Apnea in children with COVID-19 has also been reported [6]. However, when the thorax stops moving, it may not be central apnea but breath-holding due to seizure. In this case, we could not indicate ictal pattern by EEG during breath holding, however, it was improved by phenobarbital, suggesting the possibility of breath-holding due to seizure. In conclusion, although COVID-19 is not severe in most children, life-threatening conditions such as COVID-19-associated severe encephalopathy can occur during the neonatal and early infantile periods.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
  17 in total

1.  Nonconvulsive status epilepticus: the encephalopathic pediatric patient.

Authors:  Hansel M Greiner; Katherine Holland; James L Leach; Paul S Horn; Andrew D Hershey; Douglas F Rose
Journal:  Pediatrics       Date:  2012-02-13       Impact factor: 7.124

2.  Cytotoxic lesions of the corpus callosum in children: Etiology, clinical and radiological features, and prognosis.

Authors:  Tuğçe Aksu Uzunhan; Hülya Maraş Genç; Büşra Kutlubay; Sevinç Kalın; Gonca Bektaş; Özge Yapıcı; Saliha Çıracı; Hatice Gülhan Sözen; Esra Şevketoğlu; Figen Palabıyık; Zeynep Gör; Nafiye Emel Çakar; Bülent Kara
Journal:  Brain Dev       Date:  2021-06-10       Impact factor: 1.961

3.  Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium.

Authors:  A Venkatesan; A R Tunkel; K C Bloch; A S Lauring; J Sejvar; A Bitnun; J-P Stahl; A Mailles; M Drebot; C E Rupprecht; J Yoder; J R Cope; M R Wilson; R J Whitley; J Sullivan; J Granerod; C Jones; K Eastwood; K N Ward; D N Durrheim; M V Solbrig; L Guo-Dong; C A Glaser
Journal:  Clin Infect Dis       Date:  2013-07-15       Impact factor: 9.079

Review 4.  Continuous electroencephalogram detection of non-convulsive seizures in the pediatric intensive care unit: review of the utility and impact on management and outcomes.

Authors:  Carey A Wilson
Journal:  Transl Pediatr       Date:  2015-10

5.  American Clinical Neurophysiology Society's Standardized Critical Care EEG Terminology: 2021 Version.

Authors:  Lawrence J Hirsch; Michael W K Fong; Markus Leitinger; Suzette M LaRoche; Sandor Beniczky; Nicholas S Abend; Jong Woo Lee; Courtney J Wusthoff; Cecil D Hahn; M Brandon Westover; Elizabeth E Gerard; Susan T Herman; Hiba Arif Haider; Gamaleldin Osman; Andres Rodriguez-Ruiz; Carolina B Maciel; Emily J Gilmore; Andres Fernandez; Eric S Rosenthal; Jan Claassen; Aatif M Husain; Ji Yeoun Yoo; Elson L So; Peter W Kaplan; Marc R Nuwer; Michel van Putten; Raoul Sutter; Frank W Drislane; Eugen Trinka; Nicolas Gaspard
Journal:  J Clin Neurophysiol       Date:  2021-01-01       Impact factor: 2.590

6.  Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study.

Authors:  Camilla E Lindan; Kshitij Mankad; Dipak Ram; Larry K Kociolek; V Michelle Silvera; Nathalie Boddaert; Stavros Michael Stivaros; Susan Palasis
Journal:  Lancet Child Adolesc Health       Date:  2020-12-16

Review 7.  Spectrum of neuroimaging mimics in children with COVID-19 infection.

Authors:  Alex Mun-Ching Wong; Cheng Hong Toh
Journal:  Biomed J       Date:  2021-11-15       Impact factor: 7.892

8.  Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.

Authors:  A Danielle Iuliano; Joan M Brunkard; Tegan K Boehmer; Elisha Peterson; Stacey Adjei; Alison M Binder; Stacy Cobb; Philip Graff; Pauline Hidalgo; Mark J Panaggio; Jeanette J Rainey; Preetika Rao; Karl Soetebier; Susan Wacaster; ChinEn Ai; Vikas Gupta; Noelle-Angelique M Molinari; Matthew D Ritchey
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2022-01-28       Impact factor: 35.301

Review 9.  How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms.

Authors:  Farnaz Nikbakht; Ali Mohammadkhanizadeh; Ekram Mohammadi
Journal:  Mult Scler Relat Disord       Date:  2020-09-28       Impact factor: 4.339

10.  Prevalence and Risk Factors of Neurologic Manifestations in Hospitalized Children Diagnosed with Acute SARS-CoV-2 or MIS-C.

Authors:  Ericka L Fink; Courtney L Robertson; Mark S Wainwright; Juan D Roa; Marlina E Lovett; Casey Stulce; Mais Yacoub; Renee M Potera; Elizabeth Zivick; Adrian Holloway; Ashish Nagpal; Kari Wellnitz; Theresa Czech; Katelyn M Even; Werther Brunow de Carvalho; Isadora Souza Rodriguez; Stephanie P Schwartz; Tracie C Walker; Santiago Campos-Miño; Leslie A Dervan; Andrew S Geneslaw; Taylor B Sewell; Patrice Pryce; Wendy G Silver; Jieru Egeria Lin; Wendy S Vargas; Alexis Topjian; Alicia M Alcamo; Jennifer L McGuire; Jesus Angel Domínguez Rojas; Jaime Tasayco Muñoz; Sue J Hong; William J Muller; Matthew Doerfler; Cydni N Williams; Kurt Drury; Dhristie Bhagat; Aaron Nelson; Dana Price; Heda Dapul; Laura Santos; Robert Kahoud; Conall Francoeur; Brian Appavu; Kristin P Guilliams; Shannon C Agner; Karen H Walson; Lindsey Rasmussen; Anna Janas; Peter Ferrazzano; Raquel Farias-Moeller; Kellie C Snooks; Chung-Chou H Chang; James Yun; Michelle E Schober
Journal:  Pediatr Neurol       Date:  2021-12-28       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.